Ferring Pharmaceuticals, Rebiotix and MyBiotics Pharma are to enter a research collaboration that focuses on live microbiota-based biotherapeutics to address bacterial vaginosis (BV).
Galmed Pharmaceuticals and MyBiotics Pharma are to join forces in a R&D collaboration looking into how the microbiome responds to a compound used to treat non-alcoholic steatohepatitis (NASH).
Microbiome therapeutics firm MyBiotics Pharma have received €2m ($2.3m) in funding by the European Union (EU) to develop technology capable of delivering personalised probiotics to tackle gut-related diseases.